(Nasdaq: GANX) Advances Towards A Potential Disruption Of A Forecasted $7.58Bn Market

Few areas of medicine are drawing as much attention

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: GANX) Advances Towards A Potential Disruption Of A Forecasted $7.58Bn Market *Get Our Updates Faster—Tap Here To Receive SMS Alerts* May 26th Greetings, Friend! Few areas of medicine are drawing as much attention as efforts to address the underlying biology of Parkinson’s disease. With the global Parkinson’s treatment market estimated at $5.65Bn in 2024 and projected to reach $7.58Bn by 2030, the opp. for meaningful impact continues to grow. One emerging biotech is developing small molecule therapies designed to restore enzyme function and potentially influence disease progression rather than only manage symptoms.  Early clinical signals and biomarker data suggest this approach could reshape expectations in neurodegenerative care and warrant a closer look as new data continues to emerge in upcoming studies. That's why, for May 26th, this Nasdaq profile is topping our watchlist: Gain Therapeutics, Inc. (Nasdaq: GANX) Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain also has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors. Leading The Discovery And Development Of Next Generation Allosteric Small Molecule Therapies Gain Therapeutics mission is to discover and develop groundbreaking medicines that transform lives and provide hope and improved quality of life to people suffering from debilitating neurodegenerative diseases, rare genetic disorders and cancer. Their clinical stage lead program GT-02287 has a best-in-class profile based on preclinical data and is currently being evaluated in a Phase 1 clinical trial. GT-02287 has disease-modifying potential in the treatment of Parkinson’s disease and has applications in other neurodegenerative diseases, including Gaucher disease, dementia with Lewy bodies, and Alzheimer’s disease. The Company's MagellanTM drug discovery platform integrates AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models to uncover novel allosteric binding sites on disease-implicated proteins across all therapeutic areas, pinpointing pockets that cannot be found or drugged with current technologies. With Magellan, Gain Therapeutics discovers novel, allosteric small molecule modulators that restore or disrupt protein function through activation, inhibition, stabilization, destabilization and targeted degradation, depending on the effect required based on the disease biology. The allosteric mechanism of action enables the Company to generate first-in-class or best-in-class product candidates, and they have applied their platform to generate the entirety of their product pipeline. Therapeutic Pipeline: Innovating Treatments for Unmet Needs Magellan™ - A Next Generation Allosteric Drug Discovery Platform Exploring and exploiting the biology of proteins Targeting proteins’ allosteric sites has become an increasingly important strategy in the design of small molecule drugs, opening up novel avenues for addressing a range of diseases, including those once considered ‘undruggable.' Unlike conventional small molecules that interact with a target protein’s natural orthosteric or active site, allosteric small molecules specifically bind to and modulate protein function at a distant site on the protein’s surface. This distinctive mechanism enables precise and selective regulation of protein activity, potentially offering advantages over traditional small-molecule medicines. Magellan™ is Gain’s platform technology that leverages AI-supported structural biology, proprietary algorithms and physics-based models powered by the cutting-edge CSCS Swiss National Supercomputing Centre to explore novel allosteric binding pockets on disease-implicating proteins. The Exploration Process - Target to Novel Molecules in as Little as 3 Months Magellan’s unique machine learning AI models evaluate the 3D structures of proteins and potential allosteric sites. By leveraging neural networks and physics-based molecular simulations, Magellan™ studies atomic positioning and dynamics to determine site interactions and ligand affinity to predict druggability of the allosteric pocket. Utilizing an automated, virtual screening methodology, Magellan™ can explore a vast chemical space of on-demand compound libraries with over 5 trillion compounds and identify proprietary, fit-for-purpose structurally targeted allosteric regulator small molecule candidates. Through Magellan™, Gain creates allosteric modulators that can affect protein function as dictated by therapeutic need, including protein stabilization, destabilization, degradation, inhibition and activation. Additionally, allosteric regulation offers an opp. to develop combination therapies when drug resistance occurs or monotherapeutic approaches targeting the active site of the protein are ineffective or result in highly off-target toxicities. GT-02287: A Disease-Modifying Therapy in Development for Parkinson’s Disease Novel Mechanism - GT-02287 binds at allosteric site, and chaperones glucocerebrosidase (GCase) enzyme to lysosomes and mitochondria Disease Modification - Restores GCase function and improves disease cascade and neuronal survival in both GBA1 and iPD models Efficacy - Phase 1b shows statistically significant biomarker evidence of central target engagement with clinical improvement measured via MDS-UPDRS scores Safety/Tolerability - Well-tolerated in both healthy volunteers and PD patients with therapeutic CNS exposures achieved Next Steps - Start of Phase 2 trial in Q3 2026 GT-02287 Evidence: Patients with elevated baseline CSF GluSph had an average 81% reduction after 90 days of treatment Elevated baseline DDC in high CSF GluSph group also reduced following 90 days of treatment Clinically relevant improvement in MDS-UPDRS Parts II + III scores of 6.2 points in high CSF GluSph group Parkinson’s Disease: High Need for Disease-Modifying Therapies Existing therapies address symptoms without slowing progression Grab Report Sources And More Here: GANX Website. GANX Presentation. ----- 5 Key Reasons Why (Nasdaq: GANX) Holds Our Top Watchlist Spot Thursday #1. An Average Of 5 Analyst Targets May Suggest GANX To Be Undervalued From Current Chart Levels. Take a look at this info found over at MarketBeat: 5 separate analyst targets are pointing to an average target of $8.50 according to MarketBeat. From Friday's close, that $8.50 target represents a potential 375+% upside. From current chart levels, does this averaged target signal (Nasdaq: GANX) to be undervalued? #2. Advancing Clinical Evidence Positions GT-02287 As Transformative Parkinson's Treatment Candidate. Gain Therapeutics is building a compelling clinical profile for GT-02287, supported by emerging biomarker and patient data from its ongoing Phase 1b study. The therapy has demonstrated central target engagement and meaningful biological effects, including an average 81% reduction in GluSph levels in certain patients, alongside improvements in downstream disease pathways. Notably, clinical measures such as MDS-UPDRS scores have remained stable over extended dosing, suggesting sustained benefit. This combination of biological and clinical signals strengthens the case that GT-02287 may address underlying disease mechanisms rather than just symptoms, positioning Gain at the forefront of efforts to redefine how Parkinson’s disease is treated. #3. Imminent Regulatory Progress Unlocks Next Stage Of Clinical Development Expansion. A key near-term potential catalyst is Gain’s expected FDA clearance of its Investigational New Drug application in the second quarter of 2026. This milestone would enable the company to initiate a Phase 2 clinical trial in the United States by the third quarter, significantly expanding development scope and patient access. Transitioning into Phase 2 represents a critical step where earlier signals of efficacy and mechanism can be tested more broadly. The company’s ongoing engagement with the FDA and readiness to advance quickly suggest strong operational execution. #4. Expanding Pipeline Demonstrates Platform Strength Beyond Lead Parkinson's Program. Beyond its lead candidate, Gain Therapeutics is reinforcing its broader scientific platform through additional pipeline advancements. The company introduced GT-04686, a next-generation allosteric modulator discovered using its Magellan™ platform, which has shown promising activity across cellular and animal models. These results include increased enzyme activity, reduction of harmful lipid substrates, and improvements in motor and non-motor symptoms in disease models. With GT-04686 advancing toward IND-enabling studies, Gain demonstrates its ability to consistently generate new candidates targeting neurodegenerative diseases. This expanding pipeline highlights the versatility of its approach and suggests multiple avenues for future therapeutic breakthroughs. #5. A Relatively Low Float Could Create An Environment Ripe For Heightened Volatility. With roughly 41.65Mn shares in its float, the potential for heightened volatility could be significant on a daily basis for GANX. ----- We're kicking-off coverage on Gain Therapeutics, Inc. (Nasdaq: GANX). Be on the lookout for updates coming your way soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 05/26/2026 and ending on 05/26/2026 to publicly disseminate information about (GANX:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (GANX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ganx-votqw/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice